Year in Review | Published:

Rheumatoid arthritis in 2010: From the gut to the joint

Nature Reviews Rheumatology volume 7, pages 7375 (2011) | Download Citation

From evidence pointing to a possible etiologic role for microbes to the development of new strategies and agents to treat early and established disease, 2010 has seen the publication of several interesting findings in the field of rheumatoid arthritis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815–827 (2010).

  2. 2.

    et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 62, 2662–2672 (2010).

  3. 3.

    et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum. 48, 3039–3045 (2003).

  4. 4.

    et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann. Rheum. Dis. 69, 495–502 (2010).

  5. 5.

    et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann. Rheum. Dis. 69, 503–509 (2010).

  6. 6.

    et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580–1588 (2010).

  7. 7.

    et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569–2581 (2010).

  8. 8.

    et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303–1312 (2010).

  9. 9.

    et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis Rheum. doi:10.1002/art.30114.

  10. 10.

    et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60, 1895–1905 (2009).

Download references

Author information

Affiliations

  1. Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria.

    • Clemens Scheinecker
    •  & Josef S. Smolen

Authors

  1. Search for Clemens Scheinecker in:

  2. Search for Josef S. Smolen in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Clemens Scheinecker.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2010.226

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing